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Abstract
A new variant of Creutzfeldt Jacob Disease (vCJD) was identified in humans and linked to the consumption of Bovine
Spongiform Encephalopathy (BSE)-infected meat products. Recycling of ruminant tissue in meat and bone meal (MBM) has
been proposed as origin of the BSE epidemic. During this epidemic, sheep and goats have been exposed to BSE-
contaminated MBM. It is well known that sheep can be experimentally infected with BSE and two field BSE-like cases have
been reported in goats. In this work we evaluated the human susceptibility to small ruminants-passaged BSE prions by
inoculating two different transgenic mouse lines expressing the methionine (Met) allele of human PrP at codon 129 (tg650
and tg340) with several sheep and goat BSE isolates and compared their transmission characteristics with those of cattle
BSE. While the molecular and neuropathological transmission features were undistinguishable and similar to those obtained
after transmission of vCJD in both transgenic mouse lines, sheep and goat BSE isolates showed higher transmission
efficiency on serial passaging compared to cattle BSE. We found that this higher transmission efficiency was strongly
influenced by the ovine PrP sequence, rather than by other host species-specific factors. Although extrapolation of results
from prion transmission studies by using transgenic mice has to be done very carefully, especially when human
susceptibility to prions is analyzed, our results clearly indicate that Met129 homozygous individuals might be susceptible to
a sheep or goat BSE agent at a higher degree than to cattle BSE, and that these agents might transmit with molecular and
neuropathological properties indistinguishable from those of vCJD. Our results suggest that the possibility of a small
ruminant BSE prion as vCJD causal agent could not be ruled out, and that the risk for humans of a potential goat and/or
sheep BSE agent should not be underestimated.
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Introduction
Transmissible Spongiform Encephalopathies (TSEs) are fatal
neurodegenerative diseases which include Scrapie in sheep and
goats, Bovine Spongiform Encephalopathy (BSE) and Creutzfeldt-
Jakob disease (CJD) in humans. Prions, the causal agents of these
diseases are thought to be infectious protein particles essentially
composed of a misfolded isoform (PrP
Sc) of the cellular prion protein
(PrP
C) [1,2]. Scrapie has been detected more than two centuries ago,
without epidemiological evidence of human transmission. BSE was
diagnosed in cattle in the 80s [3] and subsequently acquired epidemic
characteristics in several European countries. Ten years later, a
variant form of CJD (vCJD) was identified in humans and linked to
the consumption of BSE-infected products [4,5]. During the BSE
epidemic, sheep and goats have also been exposed to BSE-
contaminated Meat and Bone Meal, so BSE transmission to these
species may have occurred [6]. Sheep and goats are experimentally
susceptible to BSE [7,8,9,10,11] and one confirmed [12] and one
suspected [13] BSE-like case have been reported in goats in France
and the United Kingdom (UK), respectively. While BSE infection is
mostly restricted to the nervous system in cattle [14,15,16,17], PrP
Sc
is widely distributed in lymphoid tissues of experimentally BSE-
infected sheep [18,19], suggesting that infected sheep could provide a
secondary and more dangerous source of BSE infection for humans.
Considering the protein-only hypothesis, one of the most
difficult aspects to explain within prion diseases is the existence
of prion strain diversity. Prion strains can be defined as isolates or
sources of prion infectivity, that when transmitted to the same
host, present distinct disease phenotypes, characterized by their
incubation times, clinical signs, PrP
Sc biochemical properties,
histopathological lesion profiles and PrP
Sc deposition patterns in
the brain [20]. Intra-species prion transmission is characterized to
be very efficient, maintaining these phenotypic traits on serial
subpassaging. Although PrP primary sequence is highly conserved
among mammals, inter-species prion propagation is limited by the
so called transmission barrier, showing often at first passage lower
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transmission barrier has been called species barrier, suggesting to
reside essentially in the degree of PrP amino acid sequence
homology between donor and receiver [22,23]. Nowadays there is
strong evidence that also PrP
Sc conformation plays a critical role,
not only in the cross-species transmission events, but also in the
existence of different prion strains [24,25,26,27,28,29].
In previous reports we demonstrated that BSE experimentally
passaged in sheep homozygous for the A136R154Q171 allele of
ovine PrP showed an enhanced virulence in transgenic mice
expressing bovine and porcine PrP, compared to the original cattle
BSE [29,30]. The susceptibility of humans to a sheep or goat
passaged BSE agent is still unknown. PrP polymorphism at codon
129, where either methionine or valine is encoded, has been
described as a key factor influencing human prion susceptibility
[31,32,33,34] and seems to be particularly important in vCJD
manifestation, as all but one clinical vCJD cases diagnosed so far
are homozygous for methionine. In an attempt to evaluate the
potential risk for humans of a sheep or goat BSE agent in this
study we analyzed the susceptibility of transgenic mice expressing
methionine 129 human PrP to sheep and goat BSE isolates.
Results
In two parallel studies, performed in two different laboratories,
the susceptibility of 2 lines of human-PrP transgenic mice to BSE
agent wasassessed without orafter an intermediatepassageineither
sheep or goat. Both human-PrP transgenic mouse lines overexpress
human M129 PrP under the mouse Prnp promoter on a mouse PrP
null background but they differ in the genetic construction, genetic
background and human PrP protein expression levels: a PAC insert,
a Sv129 background and a 6-fold expression levels for tg650 mice
[35] and a MoPrP.Xho vector, a 129Ola/B6CBA background and
a 4-fold expression levels for tg340 mice (generated as described in
Material and Methods). Tg650 (at INRA, France) and tg340 (at
CISA-INIA, Spain) were inoculated with several cattle, sheep and
goat BSE isolates (see Table 1 for a description of the isolates used).
The transmission efficiency was evaluated by the appearance of
TSE clinical symptoms and by the presence of PrP
res in the brain.
The transmission data available to date, together with those
obtained comparatively with vCJD or sCJD agents, are shown in
Tables 2 and 3.
Low transmission efficiency of cattle-BSE prions in
human-PrP mice
Both tg650 and tg340 lines were fairly susceptible to vCJD
isolates with 100% clinical attack rates and mean survival times
around 500 and 600 days post-infection (d.p.i.), respectively. These
features were stable upon subpassaging, suggesting an absence of
transmission barrier for this agent (Tables 2 and 3). Inoculation of
cattle BSE isolates to tg340 mice produced markedly different
results, as previously reported with tg650 mice [36]. At first
passage, only one out of fifteen tg340 mice inoculated with BSE2
and BSE0 isolates was scored positive for brain PrP
res and at a very
late stage (739 d.p.i.) without clear clinical signs. The remaining
inoculated mice failed to develop a clinical disease or to
accumulate detectable levels of PrP
res in the brain up to ,700
days after inoculation. On second passage performed with brain
homogenate from a PrP
res-negative mouse (succumbed at 576 dpi)
from the first passage (BSE2 isolate), 3 out of 4 inoculated tg340
mice tested positive for brain PrP
res by western blot with a survival
time of 572637 d.p.i. It is important to note that all the cattle BSE
isolates tested in this study were transmitted as efficiently as vCJD
isolates or other BSE-related sources to bovine PrP transgenic
mice (Table 2 and 3), thus suggesting that they may have a
comparable infectivity in the absence of an apparent transmission
barrier [36]. Overall, these results indicate that both human-PrP
transgenic mouse lines exhibit a strong transmission barrier to
cattle BSE, suggesting that human PrP
C Met129 is a ‘‘bad
substrate’’ for cattle BSE prions.
High transmission efficiency of sheep and goat BSE
isolates to human-PrP mice
We next examined the transmission efficiency of sheep- and goat-
passaged BSE prions. Several experimental or ‘‘natural’’ isolates of
distinct origin were selected (Table 1). Upon primary transmission
to both tg340 and tg650 mouse lines, sheep and goat BSE isolates
showed significant higher transmission ability than cattle BSE
isolates. Thus the attack rates approached 100% (clinical signs,
PrP
res detection in the brain) with almost all the sheep and goat BSE
isolates used (Tables 2 and 3). Depending on the isolate used, the
survival times varied between 571667 and 749650 d.p.i. in tg650
and 615684 - 695622 in tg340, thus much closer to the survival
times observed for vCJD isolates inoculated in these mouse models
(Tables 2 and 3). On second and third passage, 100% attack rates
were obtained with all the sheep and goat BSE isolates tested. The
incubation times were stable or for some isolates, slightly decreased
and approached that of variant CJD. Overall, these data suggest a
lower or an absence of apparent transmission barrier to sheep and
goat BSE in human PrP transgenic mice.
Importantly, the comparatively higher attack rates seen with
sheep and goat BSE isolates are not related to their initial PrP
res
content as dilution experiment results indicate that cattle BSE
isolates (Ca-BSE2 and Ca-BSE3) contained higher PrP
res levels in
their brains than the sheep and goat BSE isolates (Figure 1).
Human PrP transgenic mice accumulate vCJD-like PrP
res
following inoculation with cattle, sheep or goat BSE
Because distinct PrP
Sc conformations appear to encipher/encode
distinct strains, brain PrP
res electrophoretic mobility and glycopro-
file characterization constitutes standard criteria to distinguish
Author Summary
Prion diseases, also referred as transmissible spongiform
encephalopathies, are fatal neurodegenerative diseases
caused by proteinaceous infectious particles denominated
‘‘prions.’’ Prion diseases acquired their first real public
relevance with the outbreak of bovine spongiform
encephalopathy (BSE) (‘‘mad cow disease’’) in the United
Kingdom in the 80s and its link with the appearance of a
new, variant form of Creutzfeldt-Jakob disease in humans.
Recycling of ruminant tissues in meat and bone meal has
been proposed as origin of the BSE epidemic. During this
episode, sheep and goats have also been exposed to BSE-
contaminated meal, so transmission to this species may
have occurred. We analyzed the human susceptibility to
sheep and goat passaged-BSE prions by using transgenic
mice expressing human prion protein (PrP). When different
sheep and goat BSE isolates were inoculated in these
transgenic mice, higher susceptibility than that observed
for cattle BSE was detected and the disease manifestation
was similar to that observed in mice inoculated with the
new variant of Creutzfeldt-Jakob disease. Our findings
suggest that humans are at least equally, and might be
even more, susceptible to a sheep or goat BSE agent
compared to a cattle BSE one.
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res of human PrP tg650 and tg340
transgenic mice inoculated with cattle, sheep and goat BSE isolates
were analysed by western blot and the signature obtained was
compared to that of variant CJD (Figures 2 and 3). A typical
PrP
vCJD banding pattern, characterized by low size fragments
(,19 kDa fragment for the aglycosyl band) and prominent
diglycosylated species was consistently observed in the challenged,
PrP
res-positive mice. This signature clearly differed from that
observed after inoculation of mice with sporadic CJD (Figure 3 and
[35]). Similar results were obtained when the immunoblots were
performed with the 12B2 anti-PrP antibody, whose epitope
(89WGQGG93 according to the human PrP sequence) is known to
be poorly protected from proteinase K digestion [29,37] in vCJD
and BSE-related isolates (Figure 4). The only exception was
observed after second passage of one cattle BSE isolate (Ca-BSE2)
intg340mice,oneofthethreepositivemicepresentedabrainPrP
res
profile clearly distinct from PrP
vCJD, that was comparable to that of
typeI sCJD-inoculated tg340 mice with predominantly monoglyco-
sylated and higher size fragments (,21 kDa for the aglycosyl band)
and preserved detection by 12B2 antibody (Figure 4).
Cattle, sheep and goat BSE isolates showed similar
neuropathological features in human PrP mice
The regional distribution of PrP
res and vacuolation in the brains
are standard criteria to differentiate between strains/TSE agents
[38]. We thus compared the neuropathological phenotypes of
cattle, sheep and goat BSE agents by PrP
res histoblotting and
histopathological examination. The PrP
res deposition pattern of
cattle, sheep and goat BSE were clearly similar in both tg650 and
tg340 mice on 2
nd passage (not shown) and on 3
rd passage in
tg650. As illustrated in Figure 5, large plaque-like PrP deposits
were detected throughout the brain, predominantly in the cerebral
cortex, corpus callosum, thalamic nuclei, optic tract, brain stem
and cerebellum, a distribution which is similar to that seen in the
brains of vCJD-infected tg650 mice (Figure 5 and [35]).
At microscopic level, abundant amyloid-like plaques were
present (Figure 6), as suggested by histoblotting. These plaques
were associated with severe vacuolisation of the surrounding tissue
(‘florid like’ aspect see Figure 6), precluding the establishment of a
reliable standard lesion profile. However similar distribution of the
vacuolar changes was observed in the brain of mice inoculated
Table 1. Description of the different isolates used in this work.
Isolate
Origin
(case number) Description and references Suplier
Ca-BSE0 Fr (139) BSE naturally infected cow INRA
1
Ca-BSE0/TgBov Pool of terminally ill bovine tg110 transgenic mice inoculated with Ca-BSE0 [17,30] INIA
2
Ca-BSE2 UK (PG1199/00) BSE naturally infected cow [51,56] VLA
3
Ca-BSE2/TgBov Pool of terminally ill bovine Tg110 transgenic mice inoculated with Ca-BSE2 [51,56] INIA
2
Ca-BSE2/TgOv Pool of terminally ill ARQ/ARQ ovine TgshpIX transgenic mice [39] inoculated with Ca-BSE2 FLI
4
Ca-BSE3 Fr (3) BSE naturally infected cow [43] INRA
1
Ca-BSE4 Ge BSE passaged in tgXV mice [43] FLI
4
Ca-BSE5 It (128204) BSE naturally infected cow [43] ISS
5
Ca-BSE6 Be BSE naturally infected cow [43] LVTSEs
6
Sh-BSE0 Fr (ARQ0) Pool of terminally ill ARQ/ARQ sheep inoculated with Ca-BSE0 [17,30] INRA
1
Sh-BSE0/TgBov Pool of terminally ill bovine Tg110 transgenic mice inoculated with Sh-BSE0 [17] INIA
2
Sh-BSE0/TgOv Pool of terminally ill ARQ/ARQ ovine TgshpIX transgenic mice [39] inoculated with Sh-BSE1 FLI
4
Sh-BSE2 Fr (ARQ2) ARQ/ARQ sheep inoculated with BSE [57] AFSSA
7
Sh-BSE3 Fr (ARQ3) ARQ/ARQ sheep inoculated with BSE [57] AFSSA
7
Go-BSE1 Fr (CH636) Goat BSE case [12] AFSSA
7
Go-BSE1/TgBov 2
nd passage of bovine tg540 mice inoculated with Go-BSE1 INRA
1
Go-BSE2 UK Goat experimentally infected with BSE IAH
8
vCJD1 UK (NHBY/0014) vCJD M129M infected case [58] NIBSC
9
vCJD2 UK (NHBY0/0003) vCJD M129M infected case NIBSC
9
vCJD3 Fr1 vCJD M129M infected case [35] INSERM
10
vCJD4 Fr2 vCJD M129M infected case [35] INSERM
10
vCJD5 Fr3 vCJD M129M infected case [35] INSERM
10
sCJD1 UK (NHBX0/0001) Type I sCJD M129M infected case [58] NIBSC
9
1French National Institute for Agricultural Research (INRA), Nouzilly, France.
2Centro de Investigacio ´n en Sanidad Animal– Instituto Nacional de Investigacio ´n y Tecnologı ´a Agraria y Alimentaria (Madrid, Spain).
3Veterinary Laboratory Agency (VLA), New Haw. Addlestone, Surrey, UK.
4provided by Martin Groschup (Friedrich-Loeffler-Institut), Germany.
5National Reference Centre for TSE (ISS Torino).
6National Reference Laboratory for Veterinary TSEs (Belgium).
7National TSE Reference Laboratory (AFSSA, Lyon, France).
8provided by Nora Hunter (IAH, UK).
9CJD Resource Centre-National Institute for Biological Standards and Control, South Mimms, Potters Bar, UK.
10Institut National de la Sante ´ et la Recherche Me ´dicale (France).
doi:10.1371/journal.ppat.1001319.t001
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thalamic, hippocampal and cerebral cortex areas, while brainstem
and cerebellar cortex remained poorly affected (Figure 6).
Transmission efficiency of BSE prions into human-PrP
mouse models is strongly influenced by the agent PrP
primary sequence
Once known that the phenotypes of cattle, sheep and goat BSE
appear indistinguishable in human PrP mice, we proceed to
analyze in more detail the potential elements involved in the
change on BSE transmission characteristics after passage into
sheep or goat. One of the cattle BSE isolate studied (Ca-BSE2) was
passaged into bovine (tg110) and ovine PrP transgenic mice (ARQ
allele) [39] to propagate BSE agents with different PrP primary
sequence (these isolates were termed Ca-BSE2/TgBov and Ca-
BSE2/TgOv, Table 1). The Ca-BSE2/TgBov isolate did not
induce a clinical disease nor PrP
res accumulation in tg340 mice
while an intermediate passage on the ovine PrP
ARQ sequence (Ca-
BSE2/TgOv) restored the disease susceptibility, with survival
times, biochemical and neuropathological features similar to those
obtained with experimental sheep BSE isolates (Figure 7 and data
not shown).
The opposite experiment was also performed. One sheep and
one goat BSE isolate were passaged (twice for goat BSE) in bovine
PrP transgenic mice (generating isolates Sh-BSE0/TgBov and Go-
BSE1/TgBov, Table 1) before re-inoculation to human PrP
transgenic mice (Figure 7). None of the mice inoculated with these
isolates developed the disease nor accumulated PrP
res, although
one of them (Sh-BSE0/tgBov) produced the shortest disease in
bovine PrP transgenic mice (Figure 7). This last result suggests that
when sheep- or goat-BSE agents recovered their original bovine
PrP sequence, the human transmission barrier was re-established.
Moreover, the Sh-BSE0/TgOv isolate (which maintains its PrP
ovine sequence) showed a full transmission rate in human
transgenic mice with similar survival times as those of the original
Sh-BSE0 isolate (Figure 7). Overall these data suggest that PrP
Sc
primary sequence plays a critical role in the capacity of BSE prions
to propagate on the human Met 129 PrP sequence.
Discussion
In this study, we compared the transmission features of cattle
and sheep/goat BSE prions in two different models of transgenic
mice expressing Met129 human PrP (tg650 and tg340 lines) in two
different laboratories. In general, the transmission results obtained
in both human-PrP transgenic mouse lines were very comparable.
Some shortening in survival times was observed in tg650 mice
(compared to the tg340 mice line), which was probably due to
higher PrP expression levels in this line. Worryingly, our results
support the view that an intermediate passage of BSE agent in
small ruminants accelerates the appearance of a vCJD-like disease
in human PrP mice or markedly increases its transmission
efficiency. Because the apparent phenotype of cattle and sheep/
goat BSE prions is conserved, these data also unravel an important
role of PrP
Sc primary sequence in the cross-species transmission
capacities of prion strains.
The transmission efficiency of cattle BSE isolates in both
human-PrP transgenic mouse models was apparently low. With all
BSE isolates, whose high infectivity has been demonstrated in
bovine-PrP transgenic mice (Tables 2 and 3), very low attack rates
were obtained on primary transmission to both tg650 and tg340
mice. Three passages were necessary to achieve a degree of fitness
comparable to vCJD in the same mouse line. This low BSE
transmission efficiency to human PrP transgenic mice -occasion-
ally accompanied by a strain shift- has also been described by
others [40,41,42], and suggests a strong although not absolute
transmission barrier. Although the exact characteristics and
further evolution of the vCJD epidemic still entail uncertainties
owing to prolonged incubation times, this apparent high
transmission barrier of humans to cattle BSE might be an
explanation for the currently low vCJD incidence, considering the
high exposure to BSE during the ‘‘mad cow’’ crisis.
Table 2. Transmission of bovine, ovine and goat-BSE isolates
to tg650 (INRA).
Isolate Mean survival time in days ± sem (n/n0)
a
BoPrP-tg540
mice HuPrP-tg650 mice
1
st passage 1
st passage 2
nd passage 3
rd passage
Ca-BSE3 29867 (9/9)
b 872 (1/6)
b,c 568665 (6/7)
b 527614 (14/14)
Ca-BSE3 29867 (9/9)
b 627; 842 (2/6)
b 677654 (7/7)
b 555624 (8/8)
Ca-BSE4 269611 (5/5)
b 802 (1/4)
b
Ca-BSE5 606–775 (0/5)
b
Ca-BSE6 360620 (6/6)
b 696–829 (0/4)
b
Sh-BSE2 27862 (6/6)
b 749650 (7/8) 596621 (8/8)
Sh-BSE3 33965 (5/5) 581660 (3/3) 462621 (5/5) 518611 (5/8)
d
Go-BSE1 25369 (6/6)
b 571667 (5/5) 597616 (9/9) 534612 (7/7)
Go-BSE2 343698(5/5) 736644 (6/6)
vCJD1 34368 (5/5)
b 506641 (6/10)
b 491637 (7/7)
b 497618 (10/10)
b
vCJD2 518611 (10/10)
vCJD3 522618 (5/5)
b 520626 (7/7)
b
vCJD4 512615 (8/8)
b
vCJD5 515641 (8/8)
b
aIntracerebral inoculation with 2 mg brain tissue equivalent; n/n0: diseased,
PrP
res: positive/inoculated animals.
bData from Beringue et al. [35,36].
c1
st passage in hemizygous mice.
dOngoing experiment (three animals still alive).
doi:10.1371/journal.ppat.1001319.t002
Table 3. Transmission of bovine, ovine and goat-BSE isolates
to tg340 (CISA).
Isolates Mean survival time in days ± sem (n/n0)
a
BoPrP-tg110 mice HuPrP-tg340 mice
1
st passage 1
st passage 2
nd passage
Ca-BSE0 303610 (13/13)
b 739 (1/6) na
Ca-BSE2 30865 (5/5)
b 491–707 (0/9) 572637 (3/4)
Sh-BSE0 23465 (16/16)
b 615684 (4/6) 564639 (5/5)
Go-BSE1 22763 (7/7) 695622 (6/7) na
vCJD1 370633 (9/9) 626629 (6/6) 612669 (6/6)
sCJD1 21466 (5/5) 19867 (6/6)
aIntracerebral inoculation with 2 mg brain tissue equivalent; n/n0: diseased,
PrP
res: positive/inoculated animals.
bData from Espinosa et al. [29].
na, not available (experiments still ongoing).
doi:10.1371/journal.ppat.1001319.t003
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goat BSE isolates were inoculated to human PrP transgenic mouse
models. Attack rates approaching 100% were observed from the
primary passage onwards and mean incubation times were more
consistent with those measured after transmission of vCJD. On
further passaging, the neuropathological phenotype and PrP
Sc
type of cattle and sheep/goat BSE agents appeared indistinguish-
able from the vCJD agent propagated in these mice, as previously
demonstrated in bovine transgenic mice [29], thus strongly
supporting the view that the same BSE prion strain has been
propagated whatever the infecting species. Hence, these observa-
tions reproduced in two distinct human transgenic lines with
different genetic background and PrP expression levels support the
view that transmission efficiency of BSE prions is increased by an
intermediate passage in sheep or goat. Although the electropho-
retic pattern of sheep/goat and cattle BSE PrP
res appeared similar
in human-PrP transgenic mice, other assays are currently
performed to further compare the biochemical or biophysical
properties of the respective proteins are ongoing.
Importantly, the higher attack rates obtained after sheep and
goat BSE transmissions compared to cattle BSE are not in
accordance with the initial PrP
res content of these isolates. In
addition, the data from inoculation to BoPrP-Tg reporter mice
suggest that cattle BSE and sheep and goat-BSE isolates could
have similar transmission efficiency (Table 1 and 2) in the absence
of apparent transmission barrier [36]. Furthermore, when the
human PrP transgenic lines were inoculated with the BSE agent
passaged into bovine and ovine transgenic mice, the transmission
Figure 1. Comparative PrP
res contentof the cattle, sheep and goat
isolates used for tgHu bioassays. Immunoblots of brain PrP
res
detected with SHA 31 mAb. Direct sample and 1/5 dilutions were loaded
on 12% Bis-Tris gels. Molecular weights (in kDa)are shown at the left side of
the blot. Excluding the BSE0 isolate, all cattle BSE isolates presented higher
PrP
res contents than the sheep and goat BSE isolates. Cattle BSE2 and BSE3
isolates presented comparable PrP
res contents while that in the BSE0isolate
was substantially lower. The sheep and goat BSE isolates used contained
similar PrP
res quantity.
doi:10.1371/journal.ppat.1001319.g001
Figure 2. Western blots analysis of PrP
res in the brains of tg650
mice infected with human, bovine, ovine and goat isolates.
Immunoblots of brain PrP
res detected with SHA 31 Mab. Similar amount of
brain tissue equivalent (20 mg) was loaded for adequate comparison. vCJD
isolate was loaded for comparison. Molecular weights (in kDa) are shown at
theleft sideof theblot. Similar PrP
res banding patterns wereobserved inthe
vCJD- and the cattle, sheep and goat BSE-challenged tg650 mice.
doi:10.1371/journal.ppat.1001319.g002
Figure 3. Western blots analysis of PrP
res in the brains of tg340
mice infected with human, bovine, ovine and goat isolates.
Immunoblots of brain PrP
res detected with SHA 31 Mab. Similar
quantities of PrP
res were loaded for adequate comparison. sCJD and
vCJD1 isolates were loaded for comparison. Molecular weights (in kDa)
are shown at the left side of the blot. Note the typical PrP
vCJD banding
pattern, characterized by low size fragments and prominent diglyco-
sylated species in the cattle, sheep and goat BSE-challenged mice.
These banding patterns clearly differed from that observed after
inoculation of mice with sporadic CJD.
doi:10.1371/journal.ppat.1001319.g003
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isolates (Figure 7), further supporting the crucial role of the PrP
Sc
primary sequence in the increase of transmission efficiency. Taken
together all these considerations suggest that the higher transmis-
sion efficiency of sheep and goat BSE isolates in comparison to
cattle BSE isolates cannot be linked to a higher infectious titer of
the inoculum but must be the outcome of a modification in the
pathogenicity of the agent.
Commonly, transmission barriers are determined considering
attackratesand quantifiedbymeasuringthefallinthe meansurvival
times between the first and second passage. Hence, if we consider
PrP
res detection as an indicator of successful transmission, our results
imply that humans could be significantly more susceptible to a sheep
orgoat BSEagentthantoacattleBSEagent.On the otherhand our
results suggest that cattle BSE infection could produce very long
latencyinhumans,withconversionefficiencyfarbelowthethreshold
of detectable PrP
res, which is also very worrying since it suggests the
possibility of silent carriers.
Our observations, made in two different mouse genetic
backgrounds, suggest that the different transmission properties
acquired by BSE after passage into either sheep or transgenic mice
expressing ovine PrP are strongly related to the ovine PrP primary
sequence, rather than to other host species-specific factors. Thus the
transmission barrier observed with cattle BSE was fully restored
when sheep/goat BSE experienced intermediate passaging into
bovine transgenic mice before reinoculation to human PrP mice. In
contrast, when the ovine sequence of sheep BSE was maintained,
through passage into ARQ ovine PrP transgenic mice, the efficient
transmission to human PrP mice was maintained. Apparently, an
ovine/caprine PrP
Sc sequence appears to facilitate human PrP
conversion by the BSE agent, compared to a bovine one.
The PrP primary sequence influence seems to depend strongly
on the strain involved, since no PrP
res was found in either first or
second passages of sheep scrapie in tg340 mice (unpublished
observations), suggesting no infection, in accordance with the lack
of epidemiological evidence linking scrapie with human TSE.
Moreover, the low transmission efficiency observed for the cattle
BSE agent is not exclusively linked to the bovine PrP sequence
since other uncommon BSE strains (BSE-L) are efficiently
transmitted to human-PrP mice [41,43]. Considering the confor-
mational selection model [20], our results would suggest that
M129 human PrP
C prefers a BSE PrP
Sc with conformational
characteristics templated by the ovine sequence, to a bovine BSE
PrP
Sc. Because a similar increased transmission efficiency of
sheep/goat BSE has been reported in wild type mice [44] and
transgenic mice expressing elk [45], bovine [29] and porcine [30]
PrP, the better structural compatibility conferred by sheep/goat
primary PrP
Sc sequence may not be limited to human PrP
C. One
explanation might be an alteration in the quaternary structure
(after passage into sheep/goat) generating PrP
Sc polymers less
degraded or more rapidly/easily amplified favouring or enhancing
the initial conversion. This question is currently being addressed
by sedimentation velocity [46] and PMCA experiments. Another
possibility, within the quasispecies concept [20,47], might be that
BSE prions confrontation with the sheep and goat primary PrP
sequence increases the variety of BSE substrain components, with
the following emergence of a markedly adapted component in
response to the selection pressure imposed by the interspecies
transmission events. On the other hand, this component would not
be distinguishable from bovine-passaged BSE prions due to the
current limits of the standard biological methods and/or the
molecular tools employed here to characterize prion strains.
Figure 4. Western blots analysis of PrP
res in the brains of tg340 mice infected with human, bovine and ovine isolates. Immunoblots of
brain PrP
res detected with SHA 31 and 12B2 mAbs. Similar quantities of PrP
res were loaded for adequate comparison. sCJD and vCJD1 isolates were
loaded for comparison. Molecular weights (in kDa) are shown at the left side of the blot. Both vCJD- and type I sCJD-like PrP
res were observed after
second passage of Ca-BSE2 in tg340 mice (Ca-BSE2/Tg340 2P-b and Ca-BSE2/Tg340 2P-a respectively).
doi:10.1371/journal.ppat.1001319.g004
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intermediate species can profoundly alter prion virulence for the
human species has important public-health issues, regarding
emerging and/or expanding TSEs, like atypical scrapie or CWD.
Although extrapolation of results from prion transmission
studies by using transgenic mice has to be done very carefully,
especially when human susceptibility to prions is analyzed, our
results clearly indicate that Met129 homozygous individuals might
be susceptible to a sheep or goat BSE agent at a higher degree
than to cattle BSE, and that these agents might transmit with
molecular and neuropathological properties indistinguishable from
those of vCJD. Although no vCJD cases have been described in
Val129 homozygous individuals so far it is relevant to analyze if
similar results will be observed in this genotype. This issue is
currently being addressed in transmission experiments using
transgenic mice expressing Val129 human PrP.
Taken all together, our results suggest that the possibility of a
small ruminant BSE prion as vCJD causal agent could not be ruled
out, which has important implications on public and animal health
policies. On one hand, although the exact magnitude and
characteristic of the vCJD epidemic is still unclear, its link with
cattle BSE is supported by strong epidemiological ground and
several experimental data. On the other hand, the molecular typing
performed in our studies, indicates that the biochemical character-
istics of the PrP
res detected in brains of our sheep and goat BSE-
inoculated mice seem to be indistinguishable from that observed in
vCJD. Considering the similarity in clinical manifestation of BSE-
and scrapie-affected sheep [48], a masker effect of scrapie over BSE,
as well as a potential adaptation of the BSE agent through
subsequent passages, could not be ruled out. As BSE infected sheep
PrP
Sc have been detected in many peripheral organs, small
ruminant-passaged BSE prions might be a more widespread source
of BSE infectivity compared to cattle [19,49,50]. This fact is even
more worrying since our transmission studies suggest that
apparently Met129 human PrP favours a BSE agent with ovine
rather than a bovine sequence. Finally, it is evident that, although
few natural cases have been described and so far we cannot draw
any definitive conclusion about the origin of vCJD, we can not
underestimate the risk of a potential goat and/or sheep BSE agent.
Materials and Methods
Ethics statement
Animal experiments were carried out in strict accordance with
therecommendationsintheguidelinesofthe CodeforMethodsand
Welfare Considerations in Behavioural Research with Animals
(Directive 86/609EC) and all efforts were made to minimize
suffering. Experiments were approved by the Committee on the
Figure 5. Regional distribution of PrP
res in the brain of human PrP transgenic mice infected with BSE agent passaged through
sheep, goat or human species. Histoblots of 4 representative anteroposterior mouse brain sections are shown. Comparison has been made at 3
rd
passage in tg650 mice. The patterns produced by sheep, goat and cattle BSE and variant CJD appear similar.
doi:10.1371/journal.ppat.1001319.g005
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and INIA); Permit Number: RTA06-091 and CT05-036353.
TSE isolates
The isolates used in this study are described in Table 1. For
mouse inoculation, all isolated were prepared from brain tissues as
10% (w/v) homogenates in 5% glucose.
Mouse transmission studies
The tg650 transgenic mouse line over expresses human PrP
M129 at a 6-fold level on a mouse PrP null background [35]. The
tg340 mouse line expressing about 4-fold level of human PrP
M129 on a mouse PrP null background has been generated
following the same procedure previously described for the
generation of other transgenic mouse line expressing different
Figure 6. Brain vacuolar changes and amyloid plaques in transgenic mice for the human PRNP gene (methionine 129 variant -
tg650). Hemalun-Eosin staining. Mice were inoculated with natural goat BSE (a – Bar 150 mm), cattle BSE (b: bar150 mm-e: bar 50 mm), vCJD (c: bar
150 mm-d: bar 50 mm) or experimental BSE in sheep (ARQ/ARQ genotype) (f: bar 50 mm). Vacuolar changes are associates to plaques deposits (a–b–c)
(in a *: plaques deposits). Plaques deposits often harboured typical features of florid plaques: presence of crown of vacuoles and glial cell nuclei
(d–e–f).
doi:10.1371/journal.ppat.1001319.g006
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below. Tg110 and tg540 mouse lines expresses bovine PrP at levels
approximately 8-fold that in cattle brain [51,52].
All inocula were prepared from brain tissues as 10% (w/v)
homogenates. Individually identified 6–10 week-old mice were
anesthetized and inoculated with 2 mg of brain homogenate in the
right parietal lobe using a 25-gauge disposable hypodermic needle.
Mice were observed daily and the neurological status was assessed
weekly. When progression of a TSE disease was evident or at the
end of lifespan, animals were euthanized because of ethical
reasons. Once euthanized, necropsy was performed and brain was
taken. A part of the brain was fixed by immersion in 10% formol
to quantify spongiform degeneration by histopathology and PK
resistant PrP accumulation (PrP
res) by immunohistochemistry
(IHQ) or histoblotting and the other was frozen at 220uCt o
determine presence of PrP
res by Western blot (WB). In all cases,
survival time and attack rate were calculated for each isolate.
Survival time was expressed as the mean of the survival days post
inoculation (d.p.i.) of all the mice scored positive for PrP
res, with its
correspondent standard error. Attack rate was determined as the
proportion of mice scored positive for PrP
res from all the mice
inoculated. When all mice were scored negative for PrP
res, the
survival time range was shown. Brain homogenates from PrP
res
positive mice, when available, were used for further passaging.
When all mice were scored negative for PrP
res on primary passage,
PrP
res-negative brain homogenates were used for second passage.
Western blot
175620 mg of frozen brain tissue were homogenized in 5%
glucose in distilled water in grinding tubes (Bio-Rad) adjusted to
10% (w/v) using a TeSeE
TM Precess 48
TM homogenizer (Bio-Rad)
following manufacturer instructions. Presence of PrP
res in
transgenic mice brains was determined by Western blot, following
the procedure described below and using the reagents of the
ELISA commercial test (TeSeE, Bio-Rad). 10–50 ml of a 10% (w/
v) brain homogenate were diluted in a 10% (w/v) negative sheep
brain homogenate, to obtain a 200 ml final volume. Homogenates
were incubated for 10 min at 37uC with 200 ml of a 2% proteinase
K solution (in buffer A). PrP
res was recovered as a pellet after
addition of 200 ml of buffer B and a centrifugation at 15,0006g for
7 min at 20uC. Supernatants were discarded and pellets were
dried inverted over absorbent paper for 5 min. Pellets were
solubilised in Laemmli buffer and samples were incubated for
5 min at room temperature, solubilised, and heated at 100uC for
5 min. Samples were centrifuged at 20,0006g for 15 min at 20uC
and supernatants were recovered and loaded on a 12% Bis-Tris
Figure 7. Transmission to human PrP mice of different BSE isolates generated by intermediary passages in either ovine or bovine
PrP transgenic mice. na: not available (experiments still ongoing).
aIntracerebral inoculation with 2 mg brain tissue equivalent; n/n0: diseased,
PrP
res positive/inoculated animals.
cTwo serial passages on tgBov mice.
doi:10.1371/journal.ppat.1001319.g007
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electrophoretically transferred onto PVDF or nitrocellulose
membranes (Millipore). Membranes were blocked O/N with 2%
BSA blocking buffer. For immunoblotting, membranes were
incubated with either Sha 31 [53] or 12B2 [37] monoclonal
antibody (Mab). Immunocomplexes were detected incubating the
membranes for 1 hour with horseradish peroxidase conjugated
anti mouse IgG (Amersham Pharmacia Biotech). Immunoblots
were developed with enhanced chemiluminescence ECL Plus (GE
Healthcare Amersham Biosciences).
Histopathology
All procedures involving mice brains were performed as
previously described [54]. Brain slices were realized, in order to
allow lesion profiling according to the standard method described
by Fraser and Dickinson [55]. Briefly, samples were fixed in
neutral-1 buffered 10% formalin (4% 2- formaldehyde) before
being cut at determined levels and paraffin embedded. After
deparaffinization, 2 mm-thick tissue sections were stained with
haematoxylin and eosin.
Histoblots
Brains were rapidly removed from euthanised mice and frozen
on dry ice. Thick 8–10 mm cryostat sections were cut, transferred
onto Superfrost slides and kept at 220uC until use. Histoblot
analyses were performed on 3 brains per infection at 2
nd and 3
rd
passage, using the 3F4 anti-PrP antibody as previously described
[35].
Generation of tg340 mouse line expressing human PrP
Tg340 mouse line expressing about 4-fold level of human PrP
M129 on a mouse PrP null background has been generated
following a similar procedure previously describe for the
generation of other transgenic mouse line expressing different
species PrP [51,56]. Briefly, the open reading frame (ORF) of
human PrP gene was isolated by PCR amplification from human
genomic DNA encoding methionine at codon 129. The primers
used created a XhoI restriction enzyme site adjacent to the
translation start and stop sites of the human PrP ORF (59 -
CTCGAGATTATGGCGAACCTTGGCTGCTGG- 39 and 59-
CTCGAGTCATCCCACTATCAGGAAGATGAG- 39, respec-
Figure 8. Brain PrP
C expression in homozygous tg340 mouse line in comparison to both tg650 mice and human brain. A)
Immunoblots of the brain PrP
C expression in tg340 detected with Pri 308 Mab. Direct sample (10% brain homogenates) and J dilutions were loaded
on 12% Bis-Tris gels. The figure illustrates a representative set of three independent experiments. B) Brain PrP
C expression in tg340 in comparison to
tg650 detected with Pri 308 Mab. Inmunoblots illustrates a representative set of three independent experiments and the diagrams represent the
mean densytometric values data from these experiments. Data from human brains (Human) were considered as 1 relative unit. Error bars represent
the standard deviation of the mean values.
doi:10.1371/journal.ppat.1001319.g008
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pGEM-T Easy Vector System (Promega) following manufacturer
instructions, and inserts were sequenced to confirm no differences
in the inferred amino acid sequence with respect to previously
sequenced human PrP genes (GenBank accession number
NM_183079) and to confirm the presence of the consequent
codon 129 nucleotide variant (MetATG). The human PrP ORF
was excised from the cloning vector using the restriction enzyme
XhoI and inserted into the expression vector MoPrP.Xho [51,56].
This vector contains the murine PrP promoter (including exon 1,
intron 1, exon 2 and 39 untranslated sequences) flanked by two
XhoI restriction sites but could be distinguished from the wild type
murine PrP gene because of the absence of intron 2. The vector
was also digested with XhoI to excise the murine PrP ORF and the
correspondent human PrP ORF were inserted by ligation,
obtaining the plasmid pMo-huPrP129M.Xho.
The human transgene was excised from the plasmid vector
using the restriction endonuclease Not I leading to DNA fragments
of approximately 12 Kb. Finally, the DNAs were purified and
dissolved in TE at a final concentration of 2 to 6 mg/ml and
microinjected into pronuclear stage ova collected from super-
ovulated B6CBAf1 females mated with 129/Ola males carrying a
null mutation in endogenous PrP [51,56].
DNA from founders’ tails biopsies was extracted using a
Extract-N-Amp Tissue PCR kit (Sigma-Aldrich) following manu-
facturer instructions. The presence of the human transgene in
these founders was identified by PCR amplification using specific
primers for the mouse PrP exon 2 and human PrP open reading
frame. The absence of the murine PrP ORF in the transgenic mice
generated was confirmed by PCR amplification using the primers:
59- TAGATGTCAAGGACCTTCAGCC- 39 and 59- GTTCCA-
CTGATTATGGGTACC -39.
Eight different lines (founders) of human PrP
C (huPrP) and
murine PrP
C (muPrP) heterozygous transgenic mice (PrP mu
+/2
hu
+/2) were obtained. The expression of human PrP
C in brain of
these mouse lines was analyzed and compared with PrP
C content
in human brain homogenate by western blot using mAb 3F4
which recognizes the 109MKHM112 epitope (numbered according
to the human PrP sequence). Human PrP
C was detected in 100%
of the tested lines (data not shown). From the initial 8 different
mouse lines heterozygous for both murine and human PrP genes
(PrP mu
+/2 hu
+/2), the mouse line named as tg340 was selected
for further experiments on the basis of the level of PrP
C expression.
Homozygous Tg340 mouse line was established backcrossing
these animals with homozygous null animals MuPrP
2/2 (Prnp
2/2)
to obtain a null murine PrP background (PrP mu
2/2 hu
+/2).
Interbreeding within these animals was performed to obtain
homozygosis for the human PrP transgen within a murine PrP
background (PrP mu
2/2 hu
+/+). The absence of murine PrP gene
was determined by PCR using specific primers. Human PrP
C
expression levels, determined more accurately in brain from
homozygous tg340 animals was about 4-fold higher than PrP
C
levels in human brain homogenates as determined by dilution
experiments in western blot (Figure 8).
Accession number
The GenBank accession number for the human Prnp gene used
in this paper is NM_183079.
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